In the Chinese pharmaceutical industry, there were 6 private equity deals announced in Q2 2023, worth a total value of $1.2bn, according to GlobalData’s Deals Database. The $315m investment by abu dhabi sovereign wealth fund, cbc group and mubadala investment in Hasten Biopharmaceutic was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In volume terms, private equity deal activity in China increased by 500% in Q2 2023 versus the previous quarter and Q2 2022.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.